USA - NYSE:DHR - US2358511028 - Common Stock
The current stock price of DHR is 184.84 USD. In the past month the price decreased by -9.96%. In the past year, price decreased by -32.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 21.21 | 175.30B | ||
BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | N/A | 39.83B | ||
A | AGILENT TECHNOLOGIES INC | 22.64 | 34.98B | ||
IQV | IQVIA HOLDINGS INC | 15.65 | 30.53B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 29.45 | 24.81B | ||
WST | WEST PHARMACEUTICAL SERVICES | 37.57 | 18.81B | ||
WAT | WATERS CORP | 23.85 | 17.36B | ||
ILMN | ILLUMINA INC | 22.04 | 14.09B | ||
MEDP | MEDPACE HOLDINGS INC | 36.94 | 13.95B | ||
TEM | TEMPUS AI INC | N/A | 13.63B | ||
ICLR | ICON PLC | 12.38 | 12.74B | ||
RVTY | REVVITY INC | 17.19 | 9.76B |
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
DANAHER CORP
2200 Pennsylvania Ave NW Ste 800W
WASHINGTON WASHINGTON DC 20037 US
CEO: Rainer M. Blair
Employees: 62000
Phone: 12028280850
The current stock price of DHR is 184.84 USD. The price increased by 1.86% in the last trading session.
The exchange symbol of DANAHER CORP is DHR and it is listed on the New York Stock Exchange, Inc. exchange.
DHR stock is listed on the New York Stock Exchange, Inc. exchange.
30 analysts have analysed DHR and the average price target is 247.47 USD. This implies a price increase of 33.89% is expected in the next year compared to the current price of 184.84. Check the DANAHER CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DANAHER CORP (DHR) has a market capitalization of 132.35B USD. This makes DHR a Large Cap stock.
DANAHER CORP (DHR) currently has 62000 employees.
DANAHER CORP (DHR) has a support level at 181.76 and a resistance level at 189.29. Check the full technical report for a detailed analysis of DHR support and resistance levels.
The Revenue of DANAHER CORP (DHR) is expected to grow by 3.86% in the next year. Check the estimates tab for more information on the DHR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DANAHER CORP (DHR) has a dividend yield of 0.69%. The yearly dividend amount is currently 1.05. Check the full fundamental report for a detailed analysis of DHR dividend history, reliability and sustainability.
DANAHER CORP (DHR) will report earnings on 2025-10-21, after the market close.
The PE ratio for DANAHER CORP (DHR) is 24.55. This is based on the reported non-GAAP earnings per share of 7.53 and the current share price of 184.84 USD. Check the full fundamental report for a full analysis of the valuation metrics for DHR.
The outstanding short interest for DANAHER CORP (DHR) is 1.5% of its float. Check the ownership tab for more information on the DHR short interest.
ChartMill assigns a fundamental rating of 5 / 10 to DHR. DHR has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months DHR reported a non-GAAP Earnings per Share(EPS) of 7.53. The EPS decreased by -2.84% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 14.21% | ||
ROA | 4.18% | ||
ROE | 6.52% | ||
Debt/Equity | 0.32 |
30 analysts have analysed DHR and the average price target is 247.47 USD. This implies a price increase of 33.89% is expected in the next year compared to the current price of 184.84.
For the next year, analysts expect an EPS growth of 4.87% and a revenue growth 3.86% for DHR